Ayala Pharmaceuticals Inc (ADXS)

[hdwrsft]

Blue, there's no doubt in my mind that the deal wheel will be spinning, IMO.

For example, On September 28, 2016, Pfizer (PFE) announced the completion of its acquisition of Medivation for around $14 billion. This deal has added leading metastatic prostate cancer drug Xtandi to Pfizer’s oncology portfolio.

14Bil!!! Holy moly!

Well, guess what, we'll have prostate data next quarter on top of GOG full data presentation AND an ADXS-NEO IND (Will that trigger a milestone payment??)


Next month:
-----------

Preclinical data presentation (ImVACS, December 2016)


Calendar Q1-2017:
-----------------

(Cervical) GOG-0265 full data presentation – (1H 2017)
(Prostate) Preliminary data from ADXS-PSA + pembrolizumab cohorts A + B (1H 2017)
(NEO) ADXS-NEO Active IND (1H 2017)


Calendar Q2-2017:
-----------------
(Cervical plus Head&Neck) AXAL + durvalumab cervical/head & neck – updated data (2H 2017)
(AnalCancer) FAWCETT Stage 1 data (2H 2017)


ASCO 2017 - June 2-6, 2017 Chicago, Illinois:
---------------------------------------

(Anal) Ph 2 BrUOG – 11 patients update (ASCO 2017*)
(Head&Neck) Mt Sinai/Baylor Ph 2 Head & Neck (ASCO 2017*)
(Pediatric Osteosarcoma) COG study in pediatric osteosarcoma study start (1H 2017) • Preliminary Phase 1 data (ASCO 2017*)


Q1/Q2-2018:
-----------

(Prostate) ADXS-PSA + pembrolizumab – complete enrollment of expansion cohort
(Q4 2017); data (1H 2018)